Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Paschke, Thilo
Riefler, Michelle
Schuler-Metz, Annette
Wolz, Lucie
Scherer, Gerhard
McBride, Colleen M
and
Bepler, Gerold
2001.
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Toxicology,
Vol. 168,
Issue. 3,
p.
259.
Day, Ian NM
Gu, Dongfeng
Ganderton, Rosalind H
Spanakis, Emmanuel
and
Ye, Shu
2001.
Epidemiology and the genetic basis of disease.
International Journal of Epidemiology,
Vol. 30,
Issue. 4,
p.
661.
Peet, Norton P
2002.
The utility of predictivity in drug discovery and use.
Drug Discovery Today,
Vol. 7,
Issue. 4,
p.
228.
Xu, Chun
Goodz, Shari
Sellers, Edward M.
and
Tyndale, Rachel F.
2002.
CYP2A6 genetic variation and potential consequences.
Advanced Drug Delivery Reviews,
Vol. 54,
Issue. 10,
p.
1245.
Tyndale, Rachel F.
and
Sellers, Edward M.
2002.
Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior.
Therapeutic Drug Monitoring,
Vol. 24,
Issue. 1,
p.
163.
Lerman, Caryn
Shields, Peter G
Wileyto, E Paul
Audrain, Janet
Pinto, Angela
Hawk, Larry
Krishnan, Shiva
Niaura, Ray
and
Epstein, Leonard
2002.
Pharmacogenetic investigation of smoking cessation treatment.
Pharmacogenetics,
Vol. 12,
Issue. 8,
p.
627.
Nakajima, Miki
Kuroiwa, Yukio
and
Yokoi, Tsuyoshi
2002.
INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6.
Drug Metabolism Reviews,
Vol. 34,
Issue. 4,
p.
865.
Howard, Lisa A
Ahluwalia, Jasjit S
Lin, Shih-Ku
Sellers, Edward M
and
Tyndale, Rachel F
2003.
CYP2E1*1D regulatory polymorphism.
Pharmacogenetics,
Vol. 13,
Issue. 6,
p.
321.
Sellers, Edward M.
Tyndale, Rachel F.
and
Fernandes, Leona C.
2003.
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug Discovery Today,
Vol. 8,
Issue. 11,
p.
487.
Tricker, Anthony R
2003.
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Toxicology,
Vol. 183,
Issue. 1-3,
p.
151.
Sampablo Lauro, I.
and
Angrill Paxeras, J.
2004.
Actualización en el tratamiento del tabaquismo.
Archivos de Bronconeumología,
Vol. 40,
Issue. 3,
p.
123.
O’Loughlin, J
Paradis, G
Kim, W
DiFranza, J
Meshefedjian, G
McMillan-Davey, E
Wong, S
Hanley, J
and
Tyndale, R F
2004.
Genetically decreasedCYP2A6and the risk of tobacco dependence: a prospective study of novice smokers.
Tobacco Control,
Vol. 13,
Issue. 4,
p.
422.
Lerman, C
Wileyto, E P
Patterson, F
Rukstalis, M
Audrain-McGovern, J
Restine, S
Shields, P G
Kaufmann, V
Redden, D
Benowitz, N
and
Berrettini, W H
2004.
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
The Pharmacogenomics Journal,
Vol. 4,
Issue. 3,
p.
184.
Schoedel, Kerri A
Hoffmann, Ewa B
Rao, Yushu
Sellers, Edward M
and
Tyndale, Rachel F
2004.
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Pharmacogenetics,
Vol. 14,
Issue. 9,
p.
615.
Sampablo Lauro, I.
and
Angrill Paxeras, J.
2004.
Update on the Treatment of Smoking Dependence.
Archivos de Bronconeumología ((English Edition)),
Vol. 40,
Issue. 3,
p.
123.
Spitz, Margaret R.
Wu, Xifeng
and
Mills, Gordon
2005.
Integrative Epidemiology: From Risk Assessment to Outcome Prediction.
Journal of Clinical Oncology,
Vol. 23,
Issue. 2,
p.
267.
Martin, Richard M
Gunnell, David
Pemberton, John
Frankel, Stephen
and
Davey Smith, George
2005.
Cohort Profile: The Boyd Orr cohort—an historical cohort study based on the 65 year follow-up of the Carnegie Survey of Diet and Health (1937–39).
International Journal of Epidemiology,
Vol. 34,
Issue. 4,
p.
742.
Guengerich, F. Peter
2005.
Cytochrome P450.
p.
377.
Vasconcelos, G M
Struchiner, C J
and
Suarez-Kurtz, G
2005.
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.
The Pharmacogenomics Journal,
Vol. 5,
Issue. 1,
p.
42.
Malaiyandi, Viba
Sellers, Edward M.
and
Tyndale, Rachel F.
2005.
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*.
Clinical Pharmacology & Therapeutics,
Vol. 77,
Issue. 3,
p.
145.